Xeris Biopharma Holdings (NASDAQ:XERS) said it has shipped more than 1 million units of Gvoke, its ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children aged two years and older with diabetes.
“We are proud to celebrate this major milestone of having shipped over 1 million units of Gvoke since its launch,” Xeris CEO Paul R. Edick said in a statement.
However, Edick highlighted that far too many people with diabetes are still left without protection against a potentially life-threatening severe low blood sugar event.
“Based on recently updated guidelines by the American Diabetes Association and others, we estimate that approximately 15 million people with diabetes are at increased risk of low blood sugar, a primary risk factor being on insulin, and should be carrying a ready-to-use glucagon, like Gvoke HypoPen,” he said.
Edick concluded: “We will continue to work tirelessly towards our mission of protecting as many of the 15 million as possible and call on the medical community to take responsibility to make these new standards of care your standards of practice.”
Xeris Biopharma is a growth-oriented biopharmaceutical company committed to improving patient’s lives by developing and commercializing innovative products across a range of therapies.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie